

## **Remarks**

The office has maintained the rejection of claims 1-2, 4-5 and 9-23 as obvious in view of Costantini, Sawada, and Hogg. Although the applicants respectfully traverse, the claims have been amended to be directed to a method of selectively binding ANT and inducing the MPT in a proliferating cell but not in a non-proliferating cell by administering a compound.

As previously argued, a point of distinction between the cited documents and the present invention is that the inventors have discovered that there are, in fact, compounds that selectively induce the MPT in proliferating cells but not non-proliferating cells. Support for this can be found in the Examples of the specification. There is nothing in the teaching of Costantini or any of the other cited documents that would lead a skilled person to expect that compounds may be selective for proliferating cells compared to non-proliferating cells.

In view of the foregoing, the applicants submit that claims 1, 2, 4-5 and 9-23 cannot be obvious in view of the combination of Costantini, Sawada, and Hogg.

Reconsideration of this application is respectfully requested and a favorable determination is earnestly solicited. If it is believed that a teleconference will advance prosecution, the examiner is encouraged to contact the undersigned as indicated below.

Respectfully submitted,

Date: June 1, 2010

/Michael S. Greenfield/  
Michael S. Greenfield  
Registration No. 37,142

Telephone: 312-913-0001  
Facsimile: 312-913-0002

**McDonnell Boehnen Hulbert & Berghoff LLP**  
300 South Wacker Drive  
Chicago, IL 60606